STORM Therapeutics, a Cambridge-based company, raised $56M in Series C funding. Investors include M Ventures, Pfizer Ventures, and Taiho Ventures. The funding will enhance the Phase 2 study of its lead candidate, STC-15. This candidate targets RNA modifications to treat sarcoma.
Who to call at STORM Therapeutics, and when
A new round usually means STORM Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day STORM Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at STORM Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
STORM Therapeutics
Location
Cambridge, England, United Kingdom
About
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment STORM Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeutics